Abstract: The invention relates to an innovative method for synthesis of cyclic amidines. The synthesis starts from a ?-, ?- or ?-lactone which is twofold brominated. After esterification of the carboxyl function, the bromine atoms are nucleophilically substituted and the corresponding diamino compound is obtained. The ring closure to the cyclic amidine is accomplished subsequently by reaction with orthoester, imidate or thioimidate. Owing to interposing additional steps for recovery of the diamino compound in enantiomerically pure form, the enantiomers of the cyclic amidines can be stereoselectively synthesized.

Abstract: The present invention relates to osmolyte-containing preparations for the local treatment of dry mucous membranes. It describes the use of osmolytes for the production of a medicament, medical product or cosmetic product for the prevention, therapy and/or care of dry mucous membranes. The present invention relates to topical compositions based on osmolytes to which sodium chloride and/or moisturizers can optionally be added. The group of osmolytes proposed by the invention embraces various low-molecular substances, in particular ectoine, homoectoine, hydroxyectoine, di-myo-inositol phosphate (DIP), cyclic 2,3-diphosphoglycerate (cDPG), 1,1-di-glycerol phosphate (DGP), ?-mannosylglycerate (Firoin), ?-mannosylglyceramide (Firoin-A), di-mannosyl di-inositol phosphate (DMIP), glucosylglycerol and/or a derivative, e.g. an acid, salt or ester, of these compounds.

Abstract: The present invention relates to osmolyte-containing preparations for the local treatment of dry mucous membranes. It describes the use of osmolytes for the production of a medicament, medical product or cosmetic product for the prevention, therapy and/or care of dry mucous membranes. The present invention relates to topical compositions based on osmolytes to which sodium chloride and/or moisturizers can optionally be added. The group of osmolytes proposed by the invention embraces various low-molecular substances, in particular ectoine, homoectoine, hydroxyectoine, di-myo-inositol phosphate (DIP), cyclic 2,3-diphosphoglycerate (cDPG), 1,1-di-glycerol phosphate (DGP), ?-mannosylglycerate (Firoin), ?-mannosylglyceramide (Firoin-A), di-mannosyl di-inositol phosphate (DMIP), glucosylglycerol and/or a derivative, e.g. an acid, salt or ester, of these compounds.

Abstract: This invention is based upon the application of compatible solutes to immobilized biological materials or to immobilize in order to improve the technical performance using the same, namely nucleic acid and proteins or biosensors micronets. The above mentioned compatible solutes are selected from a group that includes Mannosylglycerate (MG) and its 3 derivatives manno-sylglyceramide (MGA), -mannosylglycerol (MGOH), and mannosyl-lactate (MGLac), 1,1-di-glycerol phosphate (DGP), ectoin, hydroxyectoin, and or derivatives or combinations thereof. The improved performance of the above mentioned techniques might be due to: a better state of preservation of the material to be immobilized, increasing the life expectancy of the material, and/or decreasing the storage and/or transport requirements, a more efficient and uniform deposition of the material on the support, more efficiency and/or specificity of hybridation of the marked material, all this originating an increase of the signal-to-noise ratio.

Abstract: A pharmaceutical formulation containing at least one protein-containing substance and at least one substance selected from the group of compatible solutes.

Abstract: A pharmaceutical formulation containing at least one protein-containing substance and at least one substance selected from the group of compatible solutes.